Current topics in behavioral neurosciences最新文献

{"title":"How Early-Life Antipsychotic Drug Administration Modifies Behavioral and Brain Function in Adulthood.","authors":"Mark E Bardgett","doi":"10.1007/7854_2024_567","DOIUrl":"https://doi.org/10.1007/7854_2024_567","url":null,"abstract":"<p><p>The use of antipsychotic drugs in children has greatly expanded over the past 30 years. This increase occurred despite a lack of research addressing how these drugs affect brain development. This review summarizes and synthesizes preclinical studies that have ascertained the short- and long-term consequences of prenatal and early postnatal antipsychotic drug administration. Antipsychotic drugs are well-known for their ability to block D₂-type dopamine receptors and this action features in two main themes that emerge from the literature. First, prenatal antipsychotic drug exposure generally leads to a long-term hypodopaminergic state while early postnatal antipsychotic drug exposure produces a hyperdopaminergic one. Second, the effects of postnatal antipsychotic drug exposure appear roughly similar regardless of age, but drug administration any time prior to puberty (pre or early postnatal) leaves a lasting imprint on neural and behavioral function that persists long after treatment cessation. The enduring brain and behavioral changes seen after early-life antipsychotic administration in animal models provide support for initiatives aimed at reducing the number of children treated with antipsychotics and limiting the dose and length of treatment for those that need them.</p>","PeriodicalId":11257,"journal":{"name":"Current topics in behavioral neurosciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fetal Alcohol Spectrum Disorders.","authors":"Riley J Felicicchia, Christina R Veziris, Sarah N Mattson","doi":"10.1007/7854_2024_569","DOIUrl":"https://doi.org/10.1007/7854_2024_569","url":null,"abstract":"<p><p>Prenatal alcohol exposure (PAE) can cause a wide range of physical, neurobehavioral, and neurocognitive impairments that impact developmental trajectories throughout the lifespan. Clinically, individuals who have been exposed to alcohol prenatally and who show physical or neurobehavioral difficulties may be classified as having a condition included in fetal alcohol spectrum disorders (FASDs). The aim of this chapter is to summarize the current knowledge of FASD including diagnostic criteria, neurobehavioral outcomes, lifespan considerations, and interventions. Individuals with PAE exhibit challenges in the cognitive domains of executive functioning, general intelligence, motor function, learning, and memory. Aggression, trouble with the law, and oppositional behavior are also commonly associated with individuals with FASD. The effects of PAE can be attributed to altered neural development such as smaller total brain volume and structural abnormalities. Prenatal exposure to alcohol increases risk for co-occurring neurodevelopmental conditions and psychiatric disorders. This chapter will also review the current literature on pre- and postnatal interventions to target the effects of PAE.</p>","PeriodicalId":11257,"journal":{"name":"Current topics in behavioral neurosciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of THC and Nicotine on Attention: A Narrative Review.","authors":"Kennedy Oleszak, Lily Freeman Striegel, Nicole Roeder, Patrick Mohr, Samantha Penman, Lorraine Collins, Danielle M Smith, Panayotis K Thanos","doi":"10.1007/7854_2024_568","DOIUrl":"https://doi.org/10.1007/7854_2024_568","url":null,"abstract":"<p><p>Since cannabis and nicotine are two of most commonly used substances and are often used together, this paper will review the effects of cannabis (specifically THC, or tetrahydrocannabinol) and nicotine on selective attention, sustained attention, visuospatial attention, attentional bias, and attentional disorders. This review includes preclinical and clinical findings throughout all periods of development and adulthood. Selective attention is directly impacted by cannabis use, while reaction time is dependent on the timing of the last cannabis exposure. Among individuals who use cannabis, there is an attentional bias that reduces anxiety and increases focus on cannabis-related cues. Preclinical studies show that cannabis induces attention deficits that persist even after an abstinence period. Preclinical and clinical studies of prenatal cannabis exposure (PCE) provide evidence that offspring will have an increased risk for drug-seeking behavior, attention deficits, and impulsivity, which may lead to attentional disorders such as attention deficit hyperactivity disorder (ADHD) and schizophrenia. Nicotine has a dose-dependent effect on attention in adults, though preclinical studies have shown mixed results, possibly due to differences in experimental design. Prenatal nicotine exposure (PNE) impairs attentional networks by increasing one's risk for ADHD, oppositional defiant disorder, and conduct disorder. Additionally, maternal secondhand smoke exposure is linked to ADHD/conduct disorder risk in offspring. Preclinical studies on prenatal nicotine exposure suggest that there may be sex differences in which males are affected more so than females with PNE. Summary: Overall, cannabis/THC impairs attention, and nicotine enhances attention; however, both substances impair attention when individuals are exposed prenatally.</p>","PeriodicalId":11257,"journal":{"name":"Current topics in behavioral neurosciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computational Approaches for Uncovering Interoceptive Mechanisms in Psychiatric Disorders and Their Biological Basis.","authors":"Marishka Mehta, Martin P Paulus, Ryan Smith","doi":"10.1007/7854_2024_572","DOIUrl":"https://doi.org/10.1007/7854_2024_572","url":null,"abstract":"<p><p>Interoception, the process of detecting, perceiving, and interpreting signals from within the body, is essential for physiological regulation and adaptive behavior. A growing body of research underscores important potential links between interoceptive dysfunction and psychiatric disorders. Parallel advancements in the field of computational psychiatry have led to the development of biologically plausible models of information processing in the brain. This review surveys the current state of traditional and computational research approaches to study interoceptive processes in psychiatry. We also provide a foundational description of predominant computational approaches and theoretical models of interoception. Finally, we discuss the potential molecular foundations of interoceptive computation and consider future directions for incorporating computational models to enhance clinical insights and inform personalized treatments. We conclude that combining interoception and computational modeling approaches holds considerable promise in moving the field forward, both in addressing unresolved mechanistic questions and identifying novel potential therapeutic targets.</p>","PeriodicalId":11257,"journal":{"name":"Current topics in behavioral neurosciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using Inhibitory Learning Theories to Optimise Treatment for Children with Anxiety Disorders.","authors":"Wenting Chen, Melissa Aji, Chloe Y S Lim, Annabel Songco, Jennifer L Hudson","doi":"10.1007/7854_2024_553","DOIUrl":"https://doi.org/10.1007/7854_2024_553","url":null,"abstract":"<p><p>Anxiety disorders in children lead to substantial impairment in functioning and development. Even the most effective gold standard treatments for childhood anxiety have 50% remission rates, suggesting a critical need to improve current treatments. Optimising exposure, the key component of anxiety treatments, represents a promising way to do so. This chapter explains how to optimise exposure outcomes for childhood anxiety through inhibitory learning theory. This chapter describes the background of inhibitory learning, including its different components and the empirical evidence supporting it. We then discuss how to improve the formation of inhibitory associations through enhancing expectancy violation, the proposed mechanism underlying inhibitory learning. Strategies to enhance inhibitory learning for child anxiety treatment are provided. These include strategies to enhance the formation of inhibitory associations, such as psychoeducation, eliminating safety signals, deepened extinction, occasional reinforced extinction, and affect-based strategies. Additionally, strategies to enhance retrieval include variability, multiple contexts, and retrieval cues. Suggestions are made on how to adapt these strategies to child populations. Further, a clinical guide for using inhibitory learning strategies in child anxiety treatment is included as an appendix. This details how clinicians can utilise these strategies to enhance current treatments, including examples of case studies and scripts.</p>","PeriodicalId":11257,"journal":{"name":"Current topics in behavioral neurosciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabinoid-based Pharmacology for the Management of Substance Use Disorders.","authors":"M Á Luján, Y Kim, L Y Zhang, J F Cheer","doi":"10.1007/7854_2024_551","DOIUrl":"https://doi.org/10.1007/7854_2024_551","url":null,"abstract":"<p><p>In the last two decades, the endocannabinoid system has emerged as a crucial modulator of motivation and emotional processing. Due to its widespread neuroanatomical distribution and characteristic retrograde signaling nature, cannabinoid type I receptors and their endogenous ligands finely orchestrate somatic and axon terminal activity of dopamine neurons. Owing to these unique features, this signaling system is a promising pharmacological target to ameliorate dopamine-mediated drug-seeking behaviors while circumventing the adverse side effects of, for instance, dopaminergic antagonists. Despite considerable preclinical efforts, an agreement on the efficacy of endocannabinoid-targeting compounds for treating drug substance use disorders in humans has not been reached. In the following chapter, we will summarize preclinical and clinical evidence addressing the therapeutic potential of cannabinoids and endocannabinoid-targeting compounds in substance use disorders. To bridge the gap between animal and clinical research, we capitalize on studies evaluating the impact of endocannabinoid-targeting compounds in relevant settings, such as the management of drug relapse. Finally, we discuss the therapeutic potential of novel cannabinoid compounds that hold promise for treating substance use disorders.</p>","PeriodicalId":11257,"journal":{"name":"Current topics in behavioral neurosciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guruism and Cultic Social Dynamics in Psychedelic Practices and Organisations.","authors":"Jules Evans, Joseph Holcomb Adams","doi":"10.1007/7854_2024_535","DOIUrl":"https://doi.org/10.1007/7854_2024_535","url":null,"abstract":"<p><p>This chapter explores the risks of guruism and cultic social dynamics in organisations that work with psychedelic drugs, which include therapist offices, clinics, research departments, retreat centres, training programmes, NGOs, underground ceremonies and new religious movements. It has been hypothesised, and argued by experienced practitioners, that psychedelics can increase suggestibility, amplify transference and facilitate an intense form of projective mechanisms in the recipients. They may thereby lead to ego-inflation and feelings of grandiosity and omnipotence in those giving the drugs and intensify cultic social dynamics in psychedelic communities - all of which can create conditions that make cases of harm and misconduct more likely to occur and go unreported. This chapter briefly introduces the terms 'guruism' and 'cultic social dynamics' and how these dynamics can lead to harm and abuse and then discusses how psychedelic drugs might amplify these processes, before outlining possible safeguards.</p>","PeriodicalId":11257,"journal":{"name":"Current topics in behavioral neurosciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemical Probes for Investigating the Endocannabinoid System.","authors":"Annaleah Hanske, Marc Nazaré, Uwe Grether","doi":"10.1007/7854_2024_563","DOIUrl":"https://doi.org/10.1007/7854_2024_563","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Cannabis sativa has been used therapeutically since early civilizations, with key cannabinoids Δ&lt;sup&gt;9&lt;/sup&gt;-tetrahydrocannabinol (THC) 3.1 and cannabidiol characterized in the 1960s, leading to the discovery of cannabinoid receptors type 1 (CB&lt;sub&gt;1&lt;/sub&gt;R) and type 2 (CB&lt;sub&gt;2&lt;/sub&gt;R) and the endocannabinoid system (ECS) in the 1990s. The ECS, involving endogenous ligands like 2-arachidonoylglycerol (2-AG) 1.1, anandamide (N-arachidonoylethanolamine (AEA)) 1.2, and various proteins, regulates vital processes such as sleep, appetite, and memory, and holds significant therapeutic potential, especially for neurological disorders. Small molecule-derived pharmacological tools, or chemical probes, target key components of the ECS and are crucial for target validation, mechanistic studies, pathway elucidation, phenotypic screening, and drug discovery. These probes selectively interact with specific proteins or pathways, enabling researchers to modulate target activity and observe biological effects. When they carry an additional reporter group, they are referred to as labeled chemical probes. Developed through medicinal chemistry, structural biology, and high-throughput screening, effective chemical probes must be selective, potent, and depending on their purpose meet additional criteria such as cell permeability and metabolic stability.This chapter describes high-quality labeled and unlabeled chemical probes targeting ECS constituents that have been successfully applied for various research purposes. CB&lt;sub&gt;1&lt;/sub&gt;R and CB&lt;sub&gt;2&lt;/sub&gt;R, class A G protein-coupled receptors, are activated by 2-AG 1.1, AEA 1.2, and THC 3.1, with numerous ligands developed for these receptors. Imaging techniques like single-photon emission computed tomography, positron emission tomography, and fluorescently labeled CB&lt;sub&gt;1&lt;/sub&gt;R and CB&lt;sub&gt;2&lt;/sub&gt;R probes have enhanced CB receptor studies. CB&lt;sub&gt;2&lt;/sub&gt;R activation generally results in immunosuppressive effects, limiting tissue injury. AEA 1.2 is mainly degraded by fatty acid amide hydrolase (FAAH) or N-acylethanolamine acid amidase (NAAA) into ethanolamine and arachidonic acid (AA) 1.3. FAAH inhibitors increase endogenous fatty acid amides, providing analgesic effects without adverse effects. NAAA inhibitors reduce inflammation and pain in animal models. Diacylglycerol lipase (DAGL) is essential for 2-AG 1.1 biosynthesis, while monoacylglycerol lipase (MAGL) degrades 2-AG 1.1 into AA 1.3, thus regulating cannabinoid signaling. Multiple inhibitors targeting FAAH and MAGL have been generated, though NAAA and DAGL probe development lags behind. Similarly, advancements in inhibitors targeting endocannabinoid (eCB) cellular uptake or trafficking proteins like fatty acid-binding proteins have been slower. The endocannabinoidome (eCBome) includes the ECS and related molecules and receptors, offering therapeutic opportunities from non-THC cannabinoids and eCBome mediators. Ongoing research aims to refine chemical tools","PeriodicalId":11257,"journal":{"name":"Current topics in behavioral neurosciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current State of the Neuroscience of Fear Extinction and Its Relevance to Anxiety Disorders.","authors":"Elena Andres, Benjamin Meyer, Kenneth S L Yuen, Raffael Kalisch","doi":"10.1007/7854_2024_555","DOIUrl":"https://doi.org/10.1007/7854_2024_555","url":null,"abstract":"<p><p>The elucidation of the functional neuroanatomy of human fear, or threat, extinction has started in the 2000s by a series of enthusiastically greeted functional magnetic resonance imaging (fMRI) studies that were able to translate findings from rodent research about an involvement of the ventromedial prefrontal cortex (vmPFC) and the hippocampus in fear extinction into human models. Enthusiasm has been painfully dampened by a meta-analysis of human fMRI studies by Fullana and colleagues in 2018 who showed that activation in these areas is inconsistent, sending shock waves through the extinction research community. The present review guides readers from the field (as well as non-specialist readers desiring safe knowledge about human extinction mechanisms) during a series of exposures with corrective information. New information about extinction-related brain activation not considered by Fullana et al. will also be presented. After completion of this exposure-based fear reduction program, readers will trust that the reward learning system, the cerebellum, the vmPFC, the hippocampus, and a wider brain network are involved in human fear extinction, along with the neurotransmitters dopamine and noradrenaline. Specific elements of our exposure program include exploitation of the temporal dynamics of extinction, of the spatial heterogeneity of extinction-related brain activation, of functional connectivity methods, and of large sample sizes. Implications of insights from studies in healthy humans for the understanding and treatment of anxiety-related disorders are discussed.</p>","PeriodicalId":11257,"journal":{"name":"Current topics in behavioral neurosciences","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive Decline in Alzheimer's Disease.","authors":"Abigail A Testo, Gwenyth Roundy, Julie A Dumas","doi":"10.1007/7854_2024_527","DOIUrl":"10.1007/7854_2024_527","url":null,"abstract":"<p><p>Deficits in memory, language, and other cognitive domains that impact an individual's ability to perform necessary tasks of daily living are symptoms of dementia, which is a major cause of death and disability in older adults. As the global population continues to age, deepening our understanding of dementia is crucial. Alzheimer's disease is the leading cause of dementia and accounts for between 60% and 80% of total dementia cases. Declines in episodic memory are considered a hallmark of Alzheimer's disease and occur early in disease progression. The cognitive effects of Alzheimer's disease differ from the cognitive changes expected in nonpathological or normal aging. While some cognitive changes are expected as a part of the aging processes, the declines in cognition associated with Alzheimer's disease are to a degree that the individual diagnosed with the disease is unable to function independently in activities of daily living. In this review, we will discuss how cognition is impacted by both normal and pathological aging, with a focus on Alzheimer's disease. We describe the progressive nature of Alzheimer's disease, as well as the effects of each stage of the disease on cognition.</p>","PeriodicalId":11257,"journal":{"name":"Current topics in behavioral neurosciences","volume":" ","pages":"181-195"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142562406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}